Alzinova: On Track

This morning, Alzinova announced that they have secured production for the upcoming phase 1b trial with ALZ-101, the company’s oligomer-specific vaccine candidate. The material meets the requirements for good quality and purity.

After some headwind and delays during the last couple of years, Alzinova is now firmly on track to start the clinical trial in Q2’21. We are encouraged by the news, and we believe that it is the case among investors as well. We will go through our estimates in detail in conjunction with the study start. Until then, we reiterate our Base Case of SEK 20 per share.